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Patients on hemodialysis have a general immunodeficiency
involving both innate and adaptive responses. As the
mechanisms contributing to this defect are uncertain, we
sought to study the effects of uremia on circulating dendritic
cells (DC) in hemodialysis patients. Immunomagnetic beads
were used to isolate myeloid and plasmacytoid DCs from
healthy donors. Immune-related functions were determined
in these cells cultured in either a complete media containing
ABO-compatible serum or media containing sera from uremic
patients. The myeloid cells were analyzed for costimulatory
molecule expression and allo-stimulatory capability following
lipopolysaccharide stimulation. The production of
interferon-a following herpes-simplex virus stimulation by
the plasmacytoid cells was also measured. Myeloid DCs
incubated with uremic sera demonstrated impaired
maturation and decreased allo-stimulatory capacity. Similarly,
herpes virus-stimulated plasmacytoid DCs incubated with
uremic sera produced significantly less interferon-a
compared with cells incubated in the complete media. Both
small and large molecule uremic toxins inhibited DC
functions in vitro. Use of more efficient dialysis to improve
small molecule clearance reversed the inhibition of uremic
sera on myeloid but not plasmacytoid DC function. We have
shown that the immunodeficiency of hemodialysis patients is
due to dialyzable uremic toxins.
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Infectious complications are a common cause of morbidity
and mortality in end-stage renal disease (ESRD) patients
maintained on renal replacement therapies (e.g. hemodialysis
(HD)).1,2 In addition, ESRD patients often have a poor
response to vaccinations (e.g. hepatitis B) achieving low
therapeutic antibody titres,3 and have a higher risk of
malignancies.4 These observations suggest an underlying
generalized defect in both innate and adaptive immunity, but
the underlying mechanisms remain unclear.5
Dendritic cells (DC) are unique professional antigen-
presenting cells that coordinate both innate and adaptive
arms of the immune system.6 DC are critical in stimulating
effector cells (including naı¨ve T cells and natural killer cells)
in response to captured foreign antigens.7 There are at least
two distinct subsets of circulating DC precursors derived
from CD34þ bone-marrow hematopoietic progenitor cells in
the peripheral blood (PB). These include precursor myeloid
and precursor plasmacytoid DC,8–10 which can be easily
identified and isolated by flow cytometric cell sorting or via
immunomagnetic bead separation technique.11,12 Precursor
myeloid DC (MDC) are derived from myeloid precursors,
express CD11c and blood dendritic cell antigen (BDCA)-1
(CD1c).12 These cells are immunosurveillant cells and drive a
potent T-helper (Th) 1-type polarized immune response to
lipopolysaccharide (LPS).9 Plasmacytoid DC (PDC) are a
recently described DC subset that express cell-surface markers
CD123, BDCA-2 and 4.12 PDC are critical in antiviral and
possibly antitumour immunity by producing large amounts
of type I-interferon (IFN).13–15 The effect of renal failure on
DC function has not been extensively investigated.
In a previous study, we established that immunomagnetic
bead isolated uremic MDC and PDC from HD patients were
functionally impaired ex vivo with reduced cell-surface
costimulatory molecule expression and IFN-a production
following appropriate stimulation.16 We hypothesized that
uremic toxins accumulated at high concentrations in the sera
of HD patients inhibit blood DC functions in vivo. In this
study, we assessed the impact of uremic sera of HD patients
on MDC and PDC functions in vitro. We demonstrate that
uremic toxins of all molecular weights (MWs) contained
within the sera of HD patients inhibit DC function, and that
these effects are potentially reversable by more efficient
dialysis. Our findings provide a rationale for utilizing HD
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regimens to improve clearance of uremic toxins and enhance
overall immune function in HD patients.
RESULTS
HD patients have higher serum levels of IL-12p70
Serum interleukin (IL)-12p70 levels were significantly higher
in HD patients (n¼ 12, 43.1711.0 pg/ml) compared with
healthy controls/human AB serum (n¼ 14, below level of
detection; Mann–Whitney U-test Po0.001).
UM inhibits normal BDCA-1þ MDC functions
To determine the effect of uremic serum on BDCA-1þ MDC
function, we studied normal BDCA-1þ MDC cultured in
uremic medium (UM). UM blocked costimulatory (CD40,
CD80, and CD86) and maturation (CD83) markers on LPS-
stimulated normal BDCA-1þ MDC (sera of 410 separate
HD patients; Figure 1a). These findings translated to a
significantly reduced allo-stimulatory capacity in mixed
lymphocyte reaction (sera of five separate HD patients,
Mann–Whitney U-test Po0.001; Figure 1b).
Compared with complete medium (CM)-cultured BDCA-
1þ MDC, UM-cultured cells exhibited enhanced CD95
expression (sera of 410 separate HD patients, mean
fluorescent intensity (MFI) 5.373.8 compared with
10.676.8, respectively, P¼not statistically significant
(NS)), but similar proportion of annexin and/or propidium
iodide (PI)-positive cells (sera of three separate HD patients,
49.8713.2% compared with 57.2710.4% of total cells,
respectively, P¼NS). LPS-stimulated BDCA-1þ MDC
cultured in UM compared with CM produced a greater
amount of IL-12p70 (sera of 410 separate HD patients,
58.9710.4 pg/ml compared with 25.275.2 pg/ml, Man-
n–Whitney U-test Po0.01). The amount of IL-12p70 present
in CM and UM was below level of detection and 9.274.5 pg/ml,
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Figure 1 | Phenotypic expression and functional analysis of BDCA1þ MDC. (a) Uremic medium inhibits the expression of costimulatory
molecule on BDCA-1þ MDC. Cell-surface expression of costimulatory molecules on LPS-stimulated (10 ng/ml) normal BDCA-1þ MDC of
healthy blood donors cultured in either CM or UM for 24 h. Flow cytometric analysis revealed reduced cell surface expression of costimulatory
molecules (CD40, CD80, and CD86) and CD83 on LPS-stimulated BDCA-1þ MDC cultured in UM compared to LPS-stimulated BDCA-1þ MDC
cultured in CM (closed profiles). Open black profiles denote isotype controls. Representative histograms shown. MFI (mean7s.d.) below
histograms representative of results of 410 experiments involving the sera of 410 separate HD patients (Mann–Whitney U-test *Po0.01).
(b) Allogeneic T-cell proliferation in a BDCA-1þ MDC/T cells two-way mixed lymphocyte reaction. LPS-stimulated (10 ng/ml) normal BDCA-1þ
MDC of healthy blood donors cultured in CM for 24 h induced greater allogeneic T-cell proliferation (measured as tritiated thymidine
incorporated cells) compared with normal BDCA-1þ MDC cultured in UM for 24 h (Mann–Whitney U-test Po0.001). Result representative of five
separate experiments involving the sera of five separate HD patients.
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respectively (Mann–Whitney U-test Po0.01). These experi-
ments represent the use of between 3 and 6 healthy blood
donors’ cells.
We next sought to determine the effect of different MW
uremic toxins on BDCA-1þ MDC functions.
Small-, middle-, and large-MW uremic toxins inhibit normal
BDCA-1þ MDC functions
Increasing concentrations of urea were added to CM
containing normal BDCA-1þ MDC in quantities comparable
to ESRD patients. Increasing concentrations of urea imparted
a dose-dependent inhibition of the ability of LPS-stimulated
normal BDCA-1þ MDC to upregulate costimulatory mole-
cule/CD83 (representative of six experiments; Figure 2a–d)
and allogeneic T-cell proliferation (representative of three
experiments, normal BDCA-1þ MDC cultured in the
presence of urea 40 mmol/l induced significantly less T-cell
proliferation compared with cells cultured in CM and
lower concentrations of urea, Kruskal–Wallis test P¼ 0.04;
Figure 2e). The amount of IL-12p70 produced by LPS-
stimulated normal BDCA-1þ MDC cultured in CM
(18.877.5 pg/ml) was greater than the amount produced
by cells cultured in the presence of urea 5 mmol/l
(12.475.8 pg/ml), 20 mmol/l (2.170.3 pg/ml), and
40 mmol/l (0.570.2 pg/ml, Kruskal–Wallis test Po0.01,
representative of six experiments). CD95 expression (data
not shown) and the proportion of annexin7PI-positive LPS-
stimulated normal BDCA-1þ MDC cultured in CM7urea
was similar (49.8713.2% compared with 57.2710.4% of
total cells, respectively, P¼NS, representative of six experi-
ments). These experiments represent the use of six healthy
blood donors’ cells.
We next evaluated the effect of small/middle- (o5000
Daltons (Da)) and large-MW (45000 Da) toxins on normal
BDCA-1þ MDC function. Similar to the effect of 40 mmol/l
of urea in CM, both uremic serum fractions inhibited the
ability of LPS-stimulated normal BDCA-1þ MDC to express
costimulatory molecules and CD83 (sera of three separate
HD patients; Figure 3) and significantly inhibited allogeneic
T-cell proliferation (sera of three separate HD patients;
Figure S1, Kruskal–Wallis test P¼ 0.002). LPS-stimulated
normal BDCA-1þ MDC cultured in the presence of small/
medium- and large MW uremic serum fractions produced
significantly less IL-12p70 compared with BDCA-1þ MDC
cultured in CM (7.175.2, 5.170.3 and 25.376.1 pg/ml,
respectively, Kruskal–Wallis test Po0.01, sera of three
separate HD patients). The amount of IL-12p70 present in
CM and in small/medium and large MW uremic serum
fractions were below the level of detection. CD95 expression
(data not shown) and the proportion of annexin7PI-
positive LPS-stimulated BDCA-1þ MDC cultured in the
presence of either uremic serum fractions were comparable
with cells cultured in CM (34.7719.2 compared with
41.2721.3% of total cells, respectively, P¼NS, sera of three
separate HD patients). These experiments represent the use
of three healthy blood donors’ cells.
Uremic BDCA-1þ MDC are functionally abnormal
Freshly isolated uremic BDCA-1þ MDC from HD patients
exhibited reduced fluorescein isothiocyanate (FITC)-dextran
uptake compared with normal BDCA-1þ MDC (representa-
tive of three separate HD patients, MFI 33.378.1 and
2.371.9, respectively, Student’s t-test Po0.01; Figure 4).
Following LPS stimulation, uremic BDCA-1þ MDC cultured
in CM or autologous UM demonstrated impaired expression
of costimulatory molecules and CD83 (representative of three
separate HD patients; Figure S2). The proportion of trypan
blue staining dead uremic BDCA-1þ MDC cultured in CM
or autologous UM was similar (25712 compared with
2879% of total BDCA-1þ MDC, respectively, P¼NS).
LPS-stimulated uremic BDCA-1þ MDC cultured in UM
compared with CM produced greater amounts of IL-12p70
(54.2710.2 compared with 1.270.1 pg/ml, Student’s t-test
Po0.001, representative of three separate HD patients). The
amount of IL-12p70 in UM and CM was 9.272.1 pg/ml and
below the level of detection, respectively. As with normal
BDCA-1þ MDC cultured in UM, uremic BDCA-1þ MDC
cultured in CM or autologous UM exhibited minimal allo-
stimulatory capacity compared with normal BDCA-1þ MDC
cultured in CM (representative of three separate HD patients,
Kruskal–Wallis test P¼ 0.003; Figure 5).
PDC
UM inhibits normal BDCA-4þ PDC functions. Herpes-simplex
virus-1 (HSV-1)-stimulated normal BDCA-4þ PDC cultured
in UM produced significantly less IFN-a than PDC cultured
in CM (53.877.8 compared with 20007183.2 pg/ml,
Student’s t-test Po0.001, sera of three separate HD patients).
The proportion of trypan blue staining dead normal BDCA-
4þ PDC cultured in CM or UM was similar (3179
compared with 35712% of total cells, respectively, P¼NS),
indicating that cell death did not account for the reduction in
cytokine secretion. We next sought to determine which
components of uremic serum might explain the inhibitory
effects on BDCA-4þ PDC function.
Compared with HSV-1-stimulated normal BDCA-4þ
PDC in CM (20007183.2 pg/ml) or in the presence of
5 mmol/l of urea in CM (16427218.3 pg/ml), the presence of
20 mmol/l (102.1710.5 pg/ml) and 40 mmol/l
(54.1714.2 pg/ml) of urea in CM, (representative of three
separate experiments) or both small/middle- (32.174.4 pg/
ml) and large MW (o10 pg/ml) uremic serum fractions (sera
of three separate HD patients) inhibit IFN-a production
(Kruskal–Wallis test Po0.001). Again, the proportion of
trypan blue staining dead cells was similar in all experiments
(data not shown, P¼NS). These experiments represent the
use of nine healthy blood donors’ cells.
Uremic BDCA-4þ PDC are functionally abnormal. We have
previously shown that the ability of HSV-1-stimulated
uremic BDCA-4þ PDC from HD patients cultured in CM
and autologous UM to produce IFN-a was profoundly
reduced (47.1717.4 and 33.278.7 pg/ml compared with
200074.5 pg/ml produced by normal BDCA-4þ PDC,
1124 Kidney International (2007) 71, 1122–1131
o r i g i n a l a r t i c l e WH Lim et al.: Effect of uremia on DC function
LPS-stimulated normal BDCA-1+ myeloid DC cultured in complete medium
With urea 5 mmol/l
With urea 20 mmol/l
With urea 40 mmol/l
140 000
120 000
10 0000
80 000
60 000
40 000
20 000
0
6250 12 500 25 000 50 000 100 000
BDCA-1+ myeloid DC numbers
Results expressed as mean ± s.d. Kruskal–Wallis test *P< 0.05
BDCA-1+ myeloid DC in complete 
 medium
BDCA-1+ myeloid DC in complete 
medium with urea 20 mmol/l
BDCA-1+ myeloid DC in complete 
medium with urea 40 mmol/l
BDCA-1+ myeloid DC in complete 
medium with urea 5 mmol/l
CD40* CD80* CD83* CD86*
[3 H
 T
hy
m
id
in
e 
in
co
rp
or
at
io
n 
(c.
p.m
.)
MFI 22.3 ± 9.2 MFI 1.8±0.4 MFI 8.2±3.2 MFI 10.9 ± 4.2
MFI 9.4 ± 3.2 MFI 0.2 ± 0.2 MFI 0.3 ± 0.2 MFI 5.2 ± 2.3
MFI 7.4 ± 2.4 MFI 0.2 ± 0.1 MFI 0.3 ± 0.2 MFI 4.6 ± 3.1
MFI 0.2 ± 0.1 MFI 0.1 ± 0.1 MFI 0.1 ± 0.1 MFI 0.2 ± 0.0
a
b
c
d
e
*P< 0.04
100 101102 103 104
Ev
en
ts
Ev
en
ts
0
100101 102 103 1040
1 1
Ev
en
ts
100 100101 102103 104
CD40 PE
100 101102 103 104
Ev
en
ts
0
1
CD40 PE
100 101102 103 104
Ev
en
ts
0
1
CD40 PE
100 101102 103 104
Ev
en
ts
0
1
CD40 PE
CD80 FITC
Ev
en
ts
100101 102 103 104
0
1
CD80 FITC
Ev
en
ts
100101 102 103 104
0
1
CD80 FITC
Ev
en
ts
100101 102 103 104
0
1
CD80 FITC
FL1-Height CD86 FITC
100
101102 103 104
0
1
Ev
en
ts
100 101 102103 104
CD83 PE
0
1
Ev
en
ts
100 101 102103 104
CD83 PE
0
1
Ev
en
ts
100 101 102103 104
CD83 PE
0
1
Ev
en
ts
0
1
CD86 FITC
101102 103 104
Ev
en
ts
0
1
100
CD86 FITC
101102 103 104
Ev
en
ts
0
1
100
CD86 FITC
101102 103 104
Ev
en
ts
0
1
Figure 2 | Phenotypic expression and functional analysis of BDCA1þ MDC. (a–d) Dose-dependent inhibition of costimulatory molecules on
BDCA-1þ MDC by urea. Cell-surface expression of costimulatory molecules and CD83 on normal LPS-stimulated (10 ng/ml) BDCA-1þ MDC of
healthy blood donors cultured in CM with graded concentrations of urea for 24 h. Flow cytometric analysis revealed reduced cell-surface
expression of costimulatory molecules (CD40, CD80, and CD86) and CD83 on BDCA-1þ MDC cultured in the presence of 5, 20, and 40 mmol/l of
urea (a–d) compared with BDCA-1þ MDC cultured in the absence of urea (a, closed profiles). Open black profiles denote isotype controls.
Representative histograms shown. MFI (mean7s.d.) below histograms are representative of results of six experiments (Kruskal–Wallis test
*Po0.05). (e) High concentration of urea inhibits the allo-stimulatory capacity of BDCA-1þ MDC. The ability of LPS-stimulated BDCA-1þ MDC
cultured in the presence of urea to stimulate allogeneic T-cell proliferation in a mixed lymphocyte reaction. Normal LPS-stimulated (10 ng/ml)
BDCA-1þ MDC of healthy blood donors cultured in CM for 24 h without urea or with 5 or 20 mmol/l of urea promoted comparable T-cell
proliferation. However, BDCA-1þ MDC cultured in the presence of 40 mmol/l induced significantly less allogeneic T-cell proliferation compared
with BDCA-1þ MDC cultured in the absence or lower concentrations of urea (Kruskal–Wallis test P¼ 0.04). Result are representative of three
separate experiments.
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Kruskal–Willis test Po0.001, uremic PDC representative of
three HD patients).16 The proportion of trypan blue-staining
dead uremic BDCA-4þ PDC cultured in CM and autologous
UM was similar (28710 and 33.1714% of total cells,
respectively, P¼NS) suggesting that our results were not
indicative of reduced PDC numbers.
Effect of more efficient dialysis on DC function
Improved dialysis efficiency reverses the inhibitory effects of
uremic serum on BDCA-1þ MDC function. To assess whether
more efficient dialysis to remove uremic toxins reverses the
inhibitory effects of uremic serum on DC functions, the effect
of uremic sera of two HD patients maintained on polyflux
LPS-stimulated normal BDCA-1+ myeloid DC cultured in complete medium
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Figure 3 | Small/medium and large uremic serum fractions inhibit the expression of costimulatory molecule on BDCA-1þ MDC.
Cell-surface expression of costimulatory molecules and CD83 on normal LPS-stimulated (10 ng/ml) BDCA-1þ MDC of healthy blood donors
cultured in the presence of small/medium and large MW uraemic serum fractions for 24 h. Flow cytometric analysis revealed reduced
cell-surface expression of costimulatory molecules (CD40, CD80, and CD86) and CD83 on BDCA-1þ MDC cultured in the presence of both
small/medium and large MW uremic serum fractions compared with BDCA-1þ MDC cultured in CM (closed profiles). Open black profiles
denote isotype controls. Representative histograms are shown. MFI (mean7s.d.) below histograms are representative of results of three
experiments involving the sera of three separate HD patients (Kruskal–Wallis test *Po0.01).
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Figure 4 | Uremic MDCs show impaired endocytic capacity but improved endocytic capacity with the change to polyflux membrane.
FITC-dextran uptake of immature immunomagnetic bead isolated uremic BDCA-1þ MDC from HD patients (n¼ 3) and following conversion
from polysulfone to polyflux membrane (n¼ 2). Flow cytometric analysis revealed reduced FITC-dextran uptake of uraemic freshly isolated
BDCA-1þ MDC (b) compared with normal freshly isolated BDCA-1þ MDC (a, closed profile, Student’s t-test Po0.001). There was an
improvement in FITC-dextran uptake of uremic freshly isolated BDCA-1þ MDC post-membrane change (c) compared with uraemic BDCA-1þ
MDC pre-membrane change (b, Student’s t-test Po0.001). Open black profiles denote control BDCA-1þ MDC incubated at 01C. Representative
histograms shown. MFI (mean7s.d.) below histograms representative of results of experiments involving three HD patients.
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membrane on normal BDCA-1þ MDC and BDCA-4þ PDC
function was analyzed. The levels of IL-12p70 detected in the
sera of HD patients maintained on polyflux membranes were
slightly reduced compared with the levels pre-membrane
change (i.e. maintained on polysulfone membrane; 19.173.5
compared with 21.176.5 pg/ml, P¼NS). LPS-stimulated
normal BDCA-1þ MDC cultured in UM (polyflux mem-
brane) displayed appropriate expression of costimulatory
molecule and CD83 (sera of two HD patients used; Figure
S3) and allogeneic T-cell proliferation compared with cells
(from the same blood donor) cultured in UM containing
serum from the same HD patient maintained on polysulfone
membrane (sera of two HD patients used; Figure S4, P¼NS).
IL-12p70 production by LPS-stimulated normal BDCA-1þ
MDC cultured in UM containing serum from the same HD
patient obtained pre- and post membrane change was similar
(60.2710.4 and 67.2719.2 pg/ml, respectively, P¼NS, sera
of two HD patients). The amount of IL-12p70 in both UM
was similar (9.372.3 and 10.275.2 pg/ml, P¼NS). CD95
expression and the proportion of annexin and/or PI-positive
cells were comparable (32712 and 29.479% of total cells,
respectively, P¼NS).
In contrast, normal BDCA-4þ PDC cultured in UM
containing serum from the same HD patient obtained pre-
(polysulfone) or post-membrane (polyflux) change demon-
strated impaired production of IFN-a compared with cells
cultured in CM (70.1714.3, 59.4719.2, and 50074.5 pg/ml,
respectively, Kruskal–Willis test Po0.001). The proportion of
trypan blue-staining dead normal BDCA-4þ PDC cultured
in medium containing the different sera was similar and
comparable to CM-cultured cells (37715 and 40.1711% of
total cells, respectively, P¼NS). These experiments represent
the use of four healthy blood donors’ cells.
Improved dialysis efficiency reverses the defect in uremic
BDCA-1þ MDC function. We next investigate whether en-
hanced dialysis with polyflux membrane translated to an
improvement in the intrinsic function of uremic BDCA-1þ
MDC ex vivo. In the same two HD patients, uremic BDCA-
1þ MDC isolated 2 months following the conversion from
polysulfone to polyflux membrane exhibited improved
endocytic capacity (MFI 2.371.9 and 17.674.3, respectively,
Student’s t-test Po0.01; Figure 4), expression of costimula-
tory molecule/CD83 (Figure 6a), and allogeneic T-cell
proliferation (representative of one HD patient, P¼NS;
Figure 6b). There were no differences in the proportion of
trypan blue-staining dead uremic BDCA-1þ MDC pre- and
postmembrane change (25712% compared with 20712%
of total MDC, respectively, P¼NS).
DISCUSSION
In these studies, we examined the mechanisms of DC
dysfunction in chronic HD patients. We have previously
shown that uremic blood MDC and PDC were functionally
impaired,16 a factor likely to contribute to the higher rates of
infectious complications observed in these patients. Thus, the
present studies were performed to examine (1) the effect of
uremic serum and its components on blood MDC and PDC
functions and (2) the effect of improved dialysis clearance on
DC functions in HD patients prospectively.
In this study, we show that uremic sera of HD patients
inhibit normal MDC and PDC functions. The presence of
uremic serum impairs MDC maturation resulting in reduced
allo-stimulatory capacity. Interestingly, the ability of UM-
cultured MDC to produce IL-12p70 was significantly
enhanced, which may reflect the well documented presence
of bioactive IL-12p70 in uremic sera of HD patients.17 IL-12
is a proinflammatory cytokine that has been shown to
enhance IL-12 production by DC via stimulation of the IL-12
receptor.18
For the first time, we demonstrated that the presence of
uremic serum inhibited normal PDC functions by diminish-
ing their ability to secrete IFN-a following HSV-1 stimulation
without affecting cell viability.
Apoptosis of immune-regulating cells such as PB mono-
nuclear cell (PBMC),19 monocytes,20 and T cells21 may have
an important role in the pathophysiology of immune
dysfunction in ESRD patients. Similarly, we demonstrated
that UM-cultured MDCs upregulate CD95 expression (Fas
molecule22,23), which may prime these cells for early
apoptosis, potentially contributing to the immune defect in
HD patients.
Uremic toxins have been isolated in the sera of CRF
patients that inhibit specific immune responses. These
comprise of soluble low- and high-MW molecules,24 includ-
ing granulocyte inhibitory protein-I,25 granulocyte inhibitory
protein-II26 and immunoglobulin light chains.27 These
molecules have been found to interfere with polymorpho-
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Figure 5 | Uraemic BDCA-1þ MDC display weak allo-stimulatory
capacity. Allogeneic T-cell proliferation in a BDCA-1þ MDC/T cells
two-way mixed lymphocyte reaction. Uremic LPS-stimulated (10 ng/
ml) BDCA-1þ MDC of HD patients cultured for 24 h in CM or
autologous UM induced minimal allogeneic T-cell proliferation. The
ability of normal LPS-stimulated BDCA-1þ MDC derived from healthy
blood donors cultured in CM and UM to stimulate allogeneic T-cell
proliferation is shown for comparison (Kruskal–Wallis test P¼ 0.003).
Result representative of three separate experiments of three separate
HD patients.
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nuclear leukocyte and lymphocyte functions,28–31 including
reduced chemotaxis, adherence, and oxidative activity in
response to phagocytosis. These toxins are readily dialyz-
able.32 In this study, we identified that small- (represented by
urea), medium- and large-MW uremic toxins within uremic
serum inhibit normal MDC and PDC functions, comparable
to the effects of uremic serum on these cells. However, it is
possible that drugs including vitamin D analogues such as
calcitriol are present within the sera of HD patients, which
may also contribute to the inhibitory effects of uremic serum
on DC functions.33 Not surprisingly, when HD patients
received more efficient dialysis following the conversion to
polyflux membranes, shown to produce better clearance of
small-MW toxins,34 there was a reversal of the inhibitory
effects of uremic serum on MDC, but not PDC functions. A
modest improvement in clearance of urea in the HD patients
100 000 Normal BDCA-1+ myeloid DC in complete
medium
Uremic BDCA-1+ myeloid DC postmembrane 
change in complete medium (polyflux)
Uremic BDCA-1+ myeloid DC premembrane
 change in complete medium (polysulfone)
60 000
50 000
30 000
90 000
80 000
70 000
40 000
20 000
10 000
0
781 1562 3125 6250 12 500 25 000 50 000
Results expressed as mean ± s.d. Kruskal – Willis test P = NS
BDCA-1+ myeloid DC numbers
[3 H
 T
hy
m
id
in
e 
in
co
rp
or
at
io
n 
(c.
p.m
.)
Freshly isolated Uremic BDCA-1+ myeloid DC postmembrane change
LPS-stimulated Uremic BDCA-1+ myeloid DC postmembrane change in complete medium
LPS-stimulated uremic BDCA-1+ myeloid DC premembrane change in complete medium
CD40* CD80* CD83* CD86*
P = 0.05
MFI 8.4 ± 2.1 MFI 0.2 ± 0.1 MFI 0.0 ± 0.0 MFI 4.5 ± 1.2
MFI 13.6 ± 3.4 MFI 4.5 ± 1.1 MFI 3.2 ± 0.8 MFI 7.9 ± 2.2
MFI 0.1 ± 0.1 MFI 0.0 ± 0.1 MFI 0.1 ± 0.1 MFI 0.1 ± 0.0
d
b
c
100 101 102 103 104
CD83-PE
100 101 102 103 104
CD83-PE
100 101 102 103 104
CD83-PE
100 101 102 103 104
CD80-FITC
100 101 102 103 104
CD80-FITC
100 101 102 103 104
CD80-FITC
100 101 102 103 104
CD40-PE
100
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
Ev
en
ts
101 102 103 104
CD40-PE
100 101 102 103 104
CD40-PE
100 101 102 103 104
CD86-FITC
100 101 102 103 104
CD86-FITC
100 101 102 103 104
CD86-FITC
00
0
0 0 0 0
0 0 0
0 0
a
Figure 6 | Phenotypic expression and functional analysis of BDCA1þ MDC. (a–c) More efficient dialysis enhances costimulatory molecule
expression on uraemic BDCA-1þ MDC. Cell surface expression of costimulatory molecules and CD83 on LPS-stimulated (10 ng/ml) uremic
BDCA-1þ MDC of HD patients (n¼ 2) obtained pre- and post-membrane change cultured in CM for 24 h. Flow cytometric analysis revealed an
upregulation of cell surface expression of costimulatory molecules (CD40, CD80, and CD86) and CD83 on uremic BDCA-1þ MDC obtained
postmembrane change following LPS stimulation in CM (b) compared with uremic BDCA-1þ MDC (of same patient) obtained pre-membrane
change (c, Student’s t-test *Po0.01). Open black profiles denote isotype controls. Representative histograms shown. MFI (mean7s.d.) below
histograms representative of results of two experiments involving two HD patients. (d) More efficient dialysis enhances allo-stimulatory
capacity of uraemic BDCA-1þ MDC. Allogeneic T-cell proliferation in a BDCA-1þ MDC/T cells two-way mixed lymphocyte reaction. Uremic LPS-
stimulated (10 ng/ml) BDCA-1þ MDC of HD patient (n¼ 1) obtained following change in membrane displayed similar allo-stimulatory capacity
as normal LPS-stimulated BDCA-1þ MDC cultured in CM for 24 h. Uremic BDCA-1þ MDC (of same patient) obtained premembrane change is
shown for comparison. Result representative of one HD patient.
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followed conversion from polysulfone to polyflux membrane,
but the effect on middle/large-MW molecules was not
determined. Polyflux membranes have also been shown to
induce less inflammatory response, potentially explaining the
marginally lower serum levels of the Th1 cytokine, IL-12p70,
following conversion. As middle and large MW uremic toxins
also inhibit DC function, consideration of using high-flux
membranes may lead to further improvement in HD patient’s
DC function, including a potential improvement in PDC
function. Further studies to define the role of high-flux
polyflux membranes on DC functions are currently underway
to determine the optimal HD regime to improve DC/
immune function in HD patients.
In this study, we demonstrate that uremic MDC from HD
patients show reduced endocytic capacity, which may in part
explain the inability of uremic MDC to undergo matura-
tion.16 We have prospectively shown that enhanced urea
clearances using polyflux membrane have resulted in an
apparent improvement in uremic MDC functions ex vivo,
which may be a direct reflection of the improvement in the
uremic environment (i.e. reduction in uremic toxins).
Supporting this finding, uremic sera of the same HD patients
maintained on polyflux membrane did not inhibit MDC
functions, in contrast to sera obtained pre-membrane
change.
From these studies, we have demonstrated that soluble
uramic toxins in HD patients inhibit both MDC and PDC
functions in vitro and ex vivo. This observed functional
impairment in DC may contribute to the widespread
immune dysfunction reported in HD patients. Our findings
indicate that improving small MW uraemic toxins clearance
by using a more efficient membrane may improve MDC
functions, consistent with other unpublished study, which
demonstrated that enhancing HD treatment may improve
immune function in CRF patients.5 A logical next step is to
confirm this initial finding by the recruitment of more
patients and then to determine which dialysis modalities
(e.g., daily HD, peritoneal dialysis etc) or membranes (e.g.,
high flux) may be superior in achieving optimal DC
functions, which may be helpful in determining the best
possible dialysis regimen in HD patients with known
immune impairment (e.g. poor or non-responders to
hepatitis B vaccination).
MATERIALS AND METHODS
Twelve HD-dependent CRF patients and 13 healthy controls were
enrolled in this study. This study was approved by the local
institutional ethics committee and informed consent was obtained
before inclusion.
In-center HD patients were maintained on intermittent thrice-
weekly HD via native arterio-venous fistulas using polysulfone
membrane (Fresenius Medical Care AG, Bad Homburg, Germany),
achieving Kt/v of 41.5. No patients had clinically significant
infections in the preceding month and patients were taking vitamin
D supplements and aspirin.
HD patients were older than healthy controls (57.2.71.5 and
43.572.4, Mann–Whitney U-test Po0.05), but had similar PB white
cell counts (6.870.6 and 6.270.3 109/l, Mann–Whitney U test
P¼ 0.8). Causes of ESRD included immune-mediated glomerulone-
phritis (n¼ 3), polycystic kidney disease (n¼ 2), diabetes mellitus
(n¼ 2), and unknown/others (n¼ 5).
Ten milliliters of peripheral venous blood were obtained from
patients and healthy controls. Blood was immediately centrifuged at
100 g for 10 min to separate serum. IL-12p70 levels were determined
in the sera by enzyme-linked immunosorbent assay (ELISA).
Remaining sera were heat inactivated for 30 min in a 561C water
bath to deactivate endogenous complement.
Reagents
FITC-, phycoerythrin-, and cychrome (CyC)-conjugated mouse
antihuman monoclonal antibodies (MAbs) were used to detect cell-
surface markers human leukocyte antigen-DR (clone G46 6), CD3
(clone SP34), CD14 (clone MY4), CD20 (clone 2H7), CD40 (clone
mAb89), CD56 (clone NCAM16.2), CD80 (clone L307.4), CD83
(clone HB15A), CD86 (clone FUN1), and CD95 (clone DX2).Iso-
type-negative controls include IgG2a (clone G155 178) and IgG2b
(clone 27 35). All MAb were obtained from BD Biosciences (San
Diego, CA) except CD40 and CD83 (Immunotech, Marseille, Cedex,
France). FITC-dextran, trypan blue, and bacterial LPS were
purchased from Sigma-Aldrich (St Louis, MO), and urea from
Bio-RAD Laboratories (Hercules, CA). MDC, PDC, and T cells were
isolated using BDCA-1, BDCA-4, and CD3 isolation kits, respec-
tively (Miltenyi Biotec, Bergisch Gladbach, Germany).35 Cell-surface
expression of annexin V and PI was detected by using a commercial
kit (Bender MedSystems, Vienna, Austria). Levels of IL-12p70 (BD
Biosciences) and IFN-a (PBL Biomedical Laboratories, Piscataway,
NJ) were determined by ELISA kits with level of detection of 7.8 and
10 pg/ml, respectively. Solutions used include Ficoll-Hypaque and
tritiated thymidine purchased from Amersham Biosciences (Brown
Deer, WI), phosphate-buffered saline (PBS) from Sigma-Aldrich,
and fluorescence-activated cell sorter lysing solution from BD
Biosciences. Fetal calf serum was obtained from JRH Biosciences
(Lenexa, KA), rabbit serum from ICN Pharmaceuticals (Costa Mesa,
CA), and human AB serum from Australia Red Cross Blood Service
(South Australia, Australia). Buffers used include staining buffer
(PBS with 1% v/v fetal calf serum and 0.1% w/v sodium azide
(Sigma-Aldrich)), and running buffer (PBS with 0.5% v/v fetal calf
serum and 2 mM ethylenediaminetetraacetate (Sigma-Aldrich)).
Rosewell Park Memorial Institute-1640 (Sigma-Aldrich) was
supplemented with 10% v/v human AB or uremic serum (ABO-
compatible with cultured cells), 2 mM L-glutamine (MultiCel Trace
Scientific, Victoria, Australia), sodium pyruvate (ICN Pharmaceu-
ticals), penicillin streptomycin (MultiCel Trace Scientific), and
sodium bicarbonate (Amresco), and referred to as CM or UM,
respectively.
Isolation of normal DC from healthy blood donors
PBMC were isolated from the buffy coat of healthy blood donors
(Australian Red Cross Blood Service) by Ficoll-Hypaque density
gradient separation, and are referred to as normal cells henceforth.
MDC and PDC were isolated from PBMC with BDCA-1 and BDCA-
4 isolation kits respectively using an automated magnetic cell
separator (Automacss, Miltenyi Biotec) as described previously
with purity of 495%.16 In brief, PBMC were labelled with anti-
CD19 and anti-BDCA-1 biotin antibodies. CD19þ B cells were
depleted by Automacss and the depleted fraction washed with
running buffer and labelled with anti-biotin antibody. BDCA-1þ
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MDC were then positively selected using the Automacss. BDCA-1þ
MDC (1 106 cells/ml) were cultured for 24 h in medium, with LPS
(10 ng/ml) added to induce maturation. Similarly, BDCA-4þ PDC
were positively selected using immunomagnetic beads by Auto-
macss after PBMC were incubated with FcR blocking antibody and
anti-BDCA-4-antibody. Following isolation, BDCA-4þ PDC
(5 105 cells/ml) were cultured in medium and stimulated with
HSV-1; (Kos strain kind donation from Keryn Williams, Flinders
Medical Centre, Adelaide, Australia) at a concentration of five
plaque-forming units per cell for 20 h. BDCA-1þ MDC and BDCA-
4þ PDC were cultured in either CM or UM in parallel under
identical conditions.
Functional analysis of normal MDC and PDC cultured
in CM and UM
LPS-stimulated BDCA-1þ MDC (1 106 cells/ml) were resus-
pended in staining buffer and incubated for 20 min with 10% v/v
rabbit serum to block nonspecific binding of antibodies to Fc
receptors. Cells (1 105) were aliquoted into polystyrene tubes (BD
Biosciences) and stained with human leukocyte antigen -DR, CD40,
CD80, CD83, CD86, and CD95 (stains for Fas ligand) MAb. Red
blood cells were lysed with fluorescence-activated cell sorter lysing
solution, and washed in staining buffer. Two-colour flow cytometric
analysis of 1 104 cells was performed with FACScans flow
cytometer with CellQuest softwares (BD Immunocytometry
Systems).
Concentrations of IL-12p70 were determined in the culture
supernatant of LPS-stimulated BDCA-1þ MDC by an ELISA kit. In
brief, 100ml of undiluted serum and standards were aliquoted into
microplates precoated with anti-human IL-12(p70) MAb. Following
incubation, the wells were washed thoroughly and 100 ml of diluted
biotinylated anti-human IL-12(p70) MAb conjugated to avidin-
horseradish peroxidase were added. Following further incubation
and washes, 200ml of substrate solution (equal volumes of hydrogen
peroxide and tetramethylbenzidine) were added and reactions
stopped by adding stop solution (1 M phosphoric acid). Optical
densities of the wells were determined using a microplate reader set
to a wavelength of 450 nm.
Apoptotic and necrotic cells were identified by cell-surface
expression of annexin V and PI respectively. In brief, cells were
washed with PBS and resuspended in binding buffer (containing
10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, 2.5 mM CaCl2)
adjusted to a cell density of 2–5 106 cells/ml of buffer. Positive
control cells were treated 30 cm under ultraviolet light for 2 min (i.e.
to render cells apoptotic) and other cells aliquoted into polystyrene
tubes and stained with appropriate volumes of Annexin V and/or
propidium iodide. Each polystyrene tube contained approximately
5 105 cells. Two-colour flow cytometric analysis of 1 104 cells
was performed within 1 h.
To investigate the allogeneic T cell stimulatory capacity of
BDCA-1þ MDC, LPS-stimulated BDCA-1þ MDC were co-cultured
with allogeneic T-cells for 5 days in a mixed lymphocyte reaction.
Allogeneic bulk T-cells were isolated by CD3 isolation kit using
Automacss achieving a purity of 495%. T cells were added to
reducing concentrations of BDCA-1þ MDC in a 96-well round
bottom plates (Techno Plastic Products, Trasadingen, Switzerland)
in triplicates starting at 1:1 BDCA-1þ MDC:T cells ratio. Cell
populations were cultured in CM and incubated in a 371C incubator
containing 5% CO2 for 5 days, with 1mCi/well of tritiated thymidine
added during the last 18 h of culture. The cells were harvested on a
96-well Tomtec harvester and radioactivity measured in a Microbeta
Trilux liquid scintillation counter (EG&G Wallac, Turku, Finland)
and results were expressed as number of tritiated thymidine
incorporated cells.
IFN-a was determined in cell-free culture supernatant of HSV-1-
stimulated BDCA-4þ PDC by an ELISA kit. In brief, 100 ml of
undiluted serum and standards were aliquoted into microplates
precoated with anti-human interferon alpha MAb. Following
incubation, the wells were washed thoroughly and 100 ml of
detection antibody added to the wells. Following incubation and
washes, 100 ml of diluted anti-secondary antibody conjugated to
horseradish peroxidase were added. Finally, 100ml of tetramethyl-
benzidine substrate solution were added to each well and reactions
stopped by adding stop solution. Optical densities of the wells were
determined using a microplate reader set to a wavelength of 450 nm.
Cell viability was assessed by trypan blue staining.
Effects of small, middle, and large MW uremic toxins on
MDC and PDC functions
To determine the effect of small MW uremic toxin on DC functions,
urea, prepared from the dilution of powder urea in distilled water,
was added to CM containing normal BDCA-1þ MDC and BDCA-
4þ PDC at a concentration of 5, 20, or 40 mmol/l. To investigate the
effects of middle- and large-MW uramic toxins on DC functions,
sera from three HD patients were separated according to MW using
ultrafree-0.5 centrifugal filter device (Millipore corporation, Bed-
ford, MA). Sera (500 ml) were aliquoted into filter devices, and
centrifuged at 10 000 g for 10 min, leaving a small/middle- (i.e.
o5000 D) and large-MW fractions (i.e. 45000 Da). Normal BDCA-
1þ MDC and BDCA-4þ PDC were cultured in media supplemen-
ted with separated serum fractions at 10% v/v (replacing AB serum),
and their functions analysed. These results were directly compared
with normal BDCA-1þ MDC and BDCA-4þ PDC (from the same
donor) cultured in CM in parallel.
Effect of more efficient dialysis on normal and uremic DC
function
We have previously shown that immunomagnetic bead isolated
uremic BDCA-1þ MDC and BDCA-4þ PDC from HD patients
exhibited impaired upregulation of costimulatory molecules and
IFN-a secretion following LPS and HSV-1 stimulation respectively.16
The membrane of these patients were subsequently changed from
polysulfone to polyfluxTM H membrane (Gambro Renal Products,
Lund, Sweden) with similar membrane surface areas. All three
patients demonstrated improved clearance (increased urea reduction
and Kt/v) following the change in membrane. Two of the three HD
patients (hemoglobin levels 4130 g/l) consented to having a further
one unit (i.e. 450 ml) of PB venesected pre-HD, thus avoiding
potential effects of HD on DC. Blood was collected in bags containing
the anticoagulant citrate phosphate 2 months following the change in
membrane. Sera of both patients were separated and the effect on
normal BDCA-1þ MDC and BDCA-4þ PDC functions analysed.
Uremic BDCA-1þ MDC from both HD patients were examined
for endocytic capacity and expression of costimulatory molecules
following culture in CM and autologous UM. Endocytosis was
assessed by the ability of BDCA-1þ MDC to capture FITC-dextran.
BDCA-1þ MDC (1 105) were incubated in CM supplemented
with 0.5 mg/ml FITC-dextran for 60 min in a 371C incubator or on
ice (negative control). Following incubation, cells were washed with
PBS and uptake of FITC-dextran determined by flow cytometric
analysis.
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Statistical analysis. All experiments were performed in
triplicates to ensure reproducibility and the representative histo-
grams for each experiment are shown. Results were expressed as
mean7s.d. Where appropriate, Mann–Whitney U-test and Welch-
corrected Student’s t-test (for two groups of data) or non-
parametric Kruskal–Wallis analysis of variance test (for three or
more groups of data) were used to compare results, with P-values
o0.05 considered statistically significant and P-valuesX0.05 as NS.
Representative histograms were shown for experiments where
appropriate, and mean7standard deviation of MFI (difference
between cell surface expression and isotype control) shown.
Statistics were performed using GraphPad Instat version 3.00
(GraphPad Software, San Diego, CA).
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SUPPLEMENTARY MATERIAL
Figure S1. Normal LPS-stimulated BDCA-1þ MDC of healthy blood
donors cultured in small/medium and large MW uremic serum
fractions induced significantly less allogeneic T-cell proliferation
compared with BDCA-1þ MDC cultured in CM (Kruskal–Wallis test
P¼ 0.002).
Figure S2. Flow cytometric analysis revealed absent/low expression
of costimulatory molecules/CD83 on freshly isolated (i) and LPS-
stimulated uremic BDCA-1þ MDC cultured in CM (ii) or autologous
UM (iii, closed profiles, Kruskal-Wallis test between groups i–iii,
P¼NS). Open black profiles denote isotype controls.
Figure S3. LPS-stimulated normal BDCA-1þ MDC cultured in UM
containing uremic serum pre-membrane change (polysulfone)
upregulated costimulatory molecules/CD83 compared with BDCA-
1þ MDC cultured in UM containing uremic serum post-membrane
change (polyflux; closed profiles, Student’s t-test Po0.01).
Figure S4. LPS-stimulated normal BDCA-1þ MDC cultured in UM
containing uremic serum pre-membrane change (polysulfone)
induced significantly less allogeneic T-cell proliferation compared
with BDCA-1þ MDC cultured in UM containing uremic serum post-
membrane change (polyflux).
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